Cargando…
Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918652/ https://www.ncbi.nlm.nih.gov/pubmed/31849317 http://dx.doi.org/10.1186/s12913-019-4829-z |
| _version_ | 1783480635596210176 |
|---|---|
| author | Mansell, Kerry Bhimji, Hishaam Eurich, Dean Mansell, Holly |
| author_facet | Mansell, Kerry Bhimji, Hishaam Eurich, Dean Mansell, Holly |
| author_sort | Mansell, Kerry |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6918652 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69186522019-12-20 Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis Mansell, Kerry Bhimji, Hishaam Eurich, Dean Mansell, Holly BMC Health Serv Res Correction BioMed Central 2019-12-18 /pmc/articles/PMC6918652/ /pubmed/31849317 http://dx.doi.org/10.1186/s12913-019-4829-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Correction Mansell, Kerry Bhimji, Hishaam Eurich, Dean Mansell, Holly Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| title | Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| title_full | Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| title_fullStr | Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| title_full_unstemmed | Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| title_short | Correction to: Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis |
| title_sort | correction to: potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in canada: a retrospective analysis |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6918652/ https://www.ncbi.nlm.nih.gov/pubmed/31849317 http://dx.doi.org/10.1186/s12913-019-4829-z |
| work_keys_str_mv | AT mansellkerry correctiontopotentialcostsavingsfromtheuseofthebiosimilarsfilgrastiminfliximabandinsulinglargineincanadaaretrospectiveanalysis AT bhimjihishaam correctiontopotentialcostsavingsfromtheuseofthebiosimilarsfilgrastiminfliximabandinsulinglargineincanadaaretrospectiveanalysis AT eurichdean correctiontopotentialcostsavingsfromtheuseofthebiosimilarsfilgrastiminfliximabandinsulinglargineincanadaaretrospectiveanalysis AT mansellholly correctiontopotentialcostsavingsfromtheuseofthebiosimilarsfilgrastiminfliximabandinsulinglargineincanadaaretrospectiveanalysis |